Claims for Patent: 8,846,315

Summary for Patent: 8,846,315

Title:	Disease risk factors and methods of use
Abstract:	Provided herein are genetic variants associated with development of a condition of interest (e.g., Alzheimer\'s disease). Methods of treatment with an active agent (e.g., with a particular active agent and/or at an earlier age) is also provided, upon detecting a genetic variant described herein. In some embodiments, the genetic variant is a deletion/insertion polymorphism (DIP) of the TOMM40 gene.
Inventor(s):	Roses; Allen D. (Chapel Hill, NC)
Assignee:	Zinfandel Pharmaceuticals, Inc. (Durham, NC)
Application Number:	13/029,713
Patent Claims:	1. A method of determining increased risk for development of Alzheimer's disease in a human subject, comprising: (a) detecting the length of a poly-T deletion/insertion polymorphism (DIP) at rs10524523 in intron 6 of the TOMM40 gene from a biological sample containing deoxyribonucleic acid taken from said subject, wherein said poly-T DIP has a length of 19, 20, 21, 22, 23, 26, 27, 28, 29, or 30; (b) correlating the detected poly-T length of 19, 20, 21, 22, 23, 26, 27, 28, 29, or 30 at rs10524523 with an increased risk of development of Alzheimer's disease; and (c) administering an anti-Alzheimer's disease active agent to said subject in an amount effective for treating said subject. 2. The method of claim 1, further comprising detecting an ApoE genotype of E2/E2, E2/E3, E2/E4, E3/E3, E3/E4, or E4/E4 in said subject. 3. The method of claim 1, wherein said detecting step includes detecting the length of a poly-T DIP at rs10524523 in each allele of the TOMM40 gene in said subject. 4. The method of claim 1, wherein said treatment effective amount is an amount effective to delay the onset of Alzheimer's disease or a symptom thereof. 5. The method of claim 1, wherein said active agent is a peroxisome proliferator-activated receptor agonist or modulator. 6. The method of claim 1, wherein said active agent is pioglitazone or a pharmaceutically acceptable salt thereof. 7. A method of treating a human subject for Alzheimer's disease by administering an active agent to said subject in a treatment-effective amount; said method comprising: administering said active agent to said subject at an earlier age when said subject carries a poly-T deletion/insertion polymorphism (DIP) at rs10524523 in intron 6 of the TOMM40, gene from a biological sample containing DNA taken from said subject, wherein said poly-T DIP has a length of 19, 20, 21, 22, 23, 26, 27, 28,29 or 30, and wherein said subject further has an ApoE 3/3 or 3/4 genotype, to thereby treat said Alzheimer's disease. 8. The method of claim 7, wherein said treating delays the onset of Alzheimer's disease or a symptom thereof. 9. The method of claim 7 wherein said active agent is a peroxisome proliferator-activated receptor agonist or modulator. 10. The method of claim 7, wherein said active agent is pioglitazone or a pharmaceutically acceptable salt thereof. 11. The method of claim 7, wherein said subject does not have an ApoE genotype of E2/2 or E2/3. 12. A method of deter ruining a risk for developing Alzheimer's disease in a human patient comprising (a) obtaining a patient profile, comprising: (i) detecting the presence or absence of at least one ApoE 2, ApoE 3, or ApoE 4 allele in a biological sample of said patient, (ii) detecting the length of a poly-T deletion/insertion polymorphism (DIP) at rs10524523 in iron 6 of the TOMM40 gene from a biological sample containing DNA taken from said patient, wherein said poly-T DIP has a length of 19, 20, 21, 22, 23, 26, 27, 28, 29, or 30, and (iii) determining that said patient is at an increased risk for developing Alzheimer's disease, and (c) administering an anti-Alzheimer's disease active agent to said patient in an amount effective for treating said patient. 13. The method of claim 12, wherein said determining step is carried out by computer program instructions. 14. The method of claim 12, wherein said detecting comprises detecting the length of a poly-T deletion/insertion polymorphism (DIP) at rs10524523 in intron 6 of the TOMM40 gene from a biological sample containing DNA taken from said patient, wherein said poly-T DIP has a length of 19, 20, 21, 22, 23, 27, 28, 29, or 30. 15. The method of claim 12, comprising detecting the absence of two ApoE2 alleles. 16. The method of claim 12, comprising detecting the presence of two ApoE4 alleles. 17. The method of claim 7, wherein said treating delays the progression of Alzheimer's disease or a symptom thereof. 18. A method of delaying the onset of Alzheimer's disease in a non-symptomatic human subject comprising: a) detecting the length of a poly-T deletion/insertion polymorphism (DIP) at rs10524523 in intron 6 of the TOMM40 gene from a biological sample containing DNA taken from said subject, wherein said poly-T DIP has a length of 19, 20, 21, 22, 23, 26, 27, 28, 29, or 30; and b) administering an active agent to said subject in an amount effective to delay the onset of Alzheimer's disease, wherein said active agent is pioglitazone or a pharmaceutically acceptable salt thereof. 19. A method of determining increased risk for development of Alzheimer's disease in a human subject, comprising: (a) detecting the presence of an ApoE genotype comprising at least one ApoE 4 or ApoE 3 allele in a biological sample containing DNA taken from said subject; (b) detecting the length of a poly-T deletion/insertion polymorphism (DIP) at rs10524523 in on 6 of the TOMM40 gene from a biological sample containing DNA taken from said subject, wherein said poly-T DIP has a length of 19, 20, 21, 22, 23, 26, 27, 28, 29, or 30 (c) correlating the detected ApoE genotype and poly-T length of 19, 20, 21, 22, 23, 26, 27, 28, 29, or 30 at rs10524523 with an increased risk of development of Alzheimer's based on: (i) the subject having an ApoE 4/4 genotype or, if the subject has an ApoE 3/4 or 3/3 genotype, the length of poly-T deletion/insertion polymorphism (DIP) at rs10524523 in intron 6 of the TOMM140 gene, and (ii) the age of the subject, and (d) administering an anti-Alzheimer's disease active agent to said subject in an amount effective for treating said subject. 20. A method of determining increased risk for development of Alzheimer's disease in a human subject, comprising: (a) detecting the subject's ApoE genotype from a biological sample containing DNA taken from said subject; (b) detecting the length of a poly-T deletion/insertion polymorphism (DIP) at rs10524523 in intron 6 of the TOMM40 gene from a biological sample containing DNA taken from said subject, wherein said poly-T DIP has a length of 19, 20, 21, 22, 23, 26, 27, 28, 29, or 30; (c) correlating the detected ApoE genotype and poly-T length of 19, 20, 21, 22, 23, 26, 27, 28, 29, or 30 at rs10524523 with an increased risk of development of Alzheimer's disease based on: (i) the subject having an ApoE 4/4 or 2/4 genotype or, if the subject has an ApoE 3/4 or 3/3 genotype, the length of poly-T deletion/insertion polymorphism (DIP) at rs10524523 in intron 6 of the TOMM40 gene, and (ii) the age of the subject; and (d) administering an anti-Alzheimer's disease active agent to said subject in an amount effective for treating said subject. 21. The method of claim 1, wherein said detecting the poly-T deletion/insertion polymorphism (DIP) at rs10524523 comprises PCR amplification and/or DNA sequencing. 22. The method of claim 19, wherein said detecting the poly-T deletion/insertion polymorphism (DIP) at rs10524523 comprises PCR amplification and/or DNA sequencing.

Details for Patent 8,846,315

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2028-08-12
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2028-08-12
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2028-08-12